WO2002043752A1 - Agents therapeutiques de potentialisation d'effet a base d'interferon - Google Patents
Agents therapeutiques de potentialisation d'effet a base d'interferon Download PDFInfo
- Publication number
- WO2002043752A1 WO2002043752A1 PCT/JP2001/010383 JP0110383W WO0243752A1 WO 2002043752 A1 WO2002043752 A1 WO 2002043752A1 JP 0110383 W JP0110383 W JP 0110383W WO 0243752 A1 WO0243752 A1 WO 0243752A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactoferrin
- interferon
- therapeutic effect
- present
- hepatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a therapeutic effect enhancer for inhalation feron containing lactoferrin as an active ingredient. More specifically, the present invention relates to various types of interferon containing metal-unsaturated lactoferrin, metal-saturated lactoferrin, or apolactoferrin (hereinafter sometimes collectively referred to as lactoferrins) as an active ingredient.
- lactoferrins various types of interferon containing metal-unsaturated lactoferrin, metal-saturated lactoferrin, or apolactoferrin (hereinafter sometimes collectively referred to as lactoferrins) as an active ingredient.
- lactoferrins an agent for enhancing the therapeutic effect of a disease.
- the present invention relates to the use of lactoferrin, a drug containing interferon and lactofurin as active ingredients, and a method for treating a disease using the drug. Background technology
- Interferon is widely used to treat diseases such as chronic hepatitis B, hepatitis C, renal cancer, and multiple myeloma.
- diseases such as chronic hepatitis B, hepatitis C, renal cancer, and multiple myeloma.
- the effect is not always high, and in particular, in cases with a high viral load, inferior feron resistance was observed, and there was a problem that a sufficient therapeutic effect was not obtained.
- the efficacy rate for chronic hepatitis C caused by Inyuichi Feronhi 2b is only 29.8%, and the rate for multiple myeloma is only 20.8%.
- the present invention has been made in view of the above circumstances, and has no side effects, is an inexpensive agent for enhancing the therapeutic effect of various diseases by in evening feron, uses an active ingredient of the enhancer, and an active ingredient of the enhancer. It is an object of the present invention to provide a drug containing quinone-fluorone as an active ingredient, and a treatment method using the drug. Presentation of the invention The present inventors have conducted intensive studies on drugs that enhance the efficacy of interferon, and as a result, focused on lactoferrin.
- Lactoferrin is a harmless and natural iron-binding protein (capable of binding two iron ions per molecule) contained in tears, saliva, peripheral blood, milk, and the like. 6, 000, human lactoferrin is 88,000 (Kazuto Imabori, supervised by Tamio Yamakawa, "Biochemical Dictionary", 2nd edition, 1390 pages, Tokyo Chemical Dojin, 19 90 years).
- Lactoferrin has antibacterial activity against harmful microorganisms such as Escherichia coli, Candida and Clostridium [Journal of Pediatrics, Vol. 94, Vol. Year], it is effective for colonizing useful bacteria such as bifidobacteria and lactic acid bacteria in the intestine of humans and animals (Patent No.
- lactofurin has an immunostimulatory effect (Japanese Patent Application Laid-Open No. Hei 7-179355), a cell proliferation effect (Japanese Patent Application Laid-Open No. Hei 6-48955), an antitumor effect [Cancer Perica- Cancer Research), Vol. 54, pp. 2310, 1994], anti-rheumatic drugs applied to therapeutic agents for diseases (JP-A-5-186368), and pharmaceuticals And hepatic function-improving agents for chronic liver injury caused by the disease (WO 00/06192).
- lactofurin has an effect of enhancing the efficacy of in evening feron in the treatment of various diseases represented by viral chronic hepatitis, and there is no literature.
- lactoferrin remarkably enhances the therapeutic effect of various diseases caused by interferon as compared with non-administration of lactoferrin, and completed the present invention.
- the use of interferon or lactoferrin alone alone can enhance the therapeutic effect of interferon-resistant high viral load viral diseases with low or no therapeutic effect. What was acknowledged was an unexpected and surprising fact.
- a first invention of the present invention that solves the above-mentioned problem is an intensified therapeutic agent containing lactoferrin as an active ingredient.
- a third aspect of the present invention for solving the above-mentioned problem is the use of lactoferrin for producing an interferon therapeutic effect enhancer.
- a fourth invention of the present invention for solving the above-mentioned problem is the use of lactoferrin for the production of an insulin-feron therapeutic effect enhancer for the treatment of viral chronic hepatitis.
- a fifth invention of the present invention is a drug comprising inuichiferon and lactoferrin as active ingredients.
- the Jie agent is for chronic hepatitis B, chronic hepatitis C, renal cancer and multiple myeloma.
- a sixth invention of the present invention for solving the above-mentioned problems is a method for treating a disease, which comprises administering such a drug.
- lactoferrins used as the active ingredient of the present invention may be commercially available products, or colostrum, transitional milk, and normal milk of mammals (eg, human, oak, sugiyu, puma, goat, sheep, etc.). And lactoferrin isolated from these processed products, such as skim milk, whey, etc., by conventional methods such as ion exchange chromatography.
- apolactophylline which is obtained by removing iron from lactoferrin by a conventional method, metal-unsaturated lactoferrin, or metal-saturated lactoferrin obtained by partially or completely chelating metals such as iron, copper, zinc, and man cancer to apolactoferrin There may be.
- human lactoferrin produced by recombinant fungi obtained by recombinant DNA technology, recombinant dairy cows (transgenic cows), etc. is also available. Can be used for invention.
- the therapeutic effect enhancer of the present invention is mixed with lactoferrin and other components, formulated into various forms by a known method, and administered.
- Specific preparations include tablets (including sugar-coated tablets, coating tablets, and balical tablets), powders, capsules, (including soft capsules), granules (including coated ones), pills, and troches. And pharmaceutically acceptable sustained-release preparations, oral preparations, enteral preparations, injection preparations and the like.
- the above-mentioned preparation is formulated as a pharmaceutical composition together with a pharmacologically acceptable carrier, excipient, disintegrant, lubricant, coloring agent and the like according to a known pharmaceutical preparation method.
- Examples of carriers and excipients used in these preparations include lactose, glucose, sucrose, mannitol, potato starch, corn starch, calcium carbonate, calcium phosphate, calcium sulfate, crystalline cellulose, canzo powder, gentian powder and the like.
- Examples of the binder include starch, gelatin, syrup, polyvinyl alcohol, polyvinyl ether, polyvinyl pyrrolidone, hydroxypropyl cellulose, ethyl cellulose, methyl cellulose, and carboxymethyl cell.
- a mouth and the like can be exemplified.
- disintegrant examples include starch, agar, gelatin powder, sodium carboxymethylcellulose, calcium carboxymethylcellulose, crystalline cellulose, calcium carbonate, sodium hydrogencarbonate, sodium alginate and the like.
- lubricating agents such as magnesium stearate, hydrogenated vegetable oil, and macrogol, and coloring agents such as Red No. 2, Yellow No. 4, and Blue No. 1, which are permitted to be added to pharmaceuticals, It can be exemplified.
- Tablets and granules may be used, if necessary, in sucrose, hydroxypropylcellulose, refined shellac, gelatin, sorbitol, glycerin, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylvinylidone, cellulose fluorate. It can also be coated with acetate, hydroxypropyl methyl cellulose phthalate, methyl methacrylate, methacrylic acid polymer and the like.
- the therapeutic effect enhancer of the present invention preferably contains at least lmg of the active ingredient lactofurin per 1 g of the drug.
- the dosage varies depending on age, symptoms, etc., but is at least lmg per 1 kg of human body weight. It is preferably administered at a dose of 20 mg to 15 g, especially 10 mg to 10 g per day.
- the form of the interferon therapeutic effect enhancer of the present invention is not limited to pharmaceuticals, and includes food and drink products represented by foods for specified health use.
- administration timing of the interferon therapeutic effect enhancer of the present invention may be before, at the same time as, or after the start of the interferon therapy.
- Interferon the efficacy of which is enhanced by the therapeutic effect enhancer of the present invention, is natural inferon-feron, inferon-feron- ⁇ , or recombinant inferon-feron. Any of interferon 2a and interferon 2b or a preparation thereof may be used.
- Diseases to be administered with the therapeutic agent for treating insulin of the present invention include: It may be any of chronic hepatitis B, hepatitis C, renal cancer, multiple myeloma, etc., for which the therapeutic effect has been recognized by feron, but especially in modern society, viral chronic hepatitis In view of the high percentage of all diseases, it is most effective to use it for the treatment of chronic viral hepatitis specified as the second invention of the present invention.
- the therapeutic agent for therapeutic effect on in evening-feron of the present invention is extremely effective against in-human evening-feron-resistant viral diseases. Therefore, as a target disease to be administered, interferon-resistant chronic hepatitis C [ Specifically, chronic hepatitis C with HCV (hepatitis C virus) genotype lb of infectious virus, or chronic hepatitis C with HCV-RNA level of at least 10 OKI U / ml ] Is recommended.
- HCV hepatitis C virus
- HCV-RNA level of at least 10 OKI U / ml chronic hepatitis C with HCV-RNA level of at least 10 OKI U / ml
- the drug of the present invention contains both components of interferon and lactoferrin as active ingredients.
- the drug is desirably used for chronic hepatitis B, chronic hepatitis C, renal cancer, and multiple myeloma. Since the drug of the present invention is extremely effective against influenza-feron-resistant viral diseases, it can be administered as an influenza-feron-resistant chronic hepatitis C [specifically, infection Chronic hepatitis C with HCV genotype 1b (Hepatitis C virus), or chronic hepatitis C with HCV-RNA level of at least 10 OKIU / ml) Especially desirable.
- influenza-feron-resistant chronic hepatitis C specifically, infection Chronic hepatitis C with HCV genotype 1b (Hepatitis C virus), or chronic hepatitis C with HCV-RNA level of at least 10 OKIU / ml
- the drug of the present invention desirably contains at least lmg of the active ingredient lactoferrin per 1 g of the drug.
- the dose varies depending on age, symptoms, etc. It is preferable to administer Omg to 5 g, especially 100 mg to 10 g.
- the drug of the present invention can be formulated into various forms by blending interferon, lactoferrin and other components by the same method as the interferon therapeutic effect enhancer.
- Test example 1 is a diagrammatic representation of Test example 1
- Lactoferrin (Morinaga Milk Industry Co., Ltd.) was used.
- HCV hepatitis C virus
- HCV genotype 1b infectious virus HCV
- HCV hepatitis C virus
- HCV genotype 2a and at least 100 HCV RNA A total of 12 patients with type I chronic hepatitis showing 111 /! 111 were randomly divided into 2 groups: 6 patients with IN-Yuichi-Feron monotherapy and 6 patients with IN-Yuichi-Fron and lactoferrin combination therapy. Subjects were the subjects.
- lactoferrin was orally administered at a dose of 1.8 g per day every day during and for 6 months after the administration of Inferior Feron.
- GPT serum glutamic-pyruvic transaminase
- lactoferrin The effects of lactoferrin on the treatment of insulin-peron are as follows.
- the effective rate of the treatment effect by each therapy group was 0%, whereas the monotherapy group was ineffective in all 6 patients, whereas the combination therapy group was 4 out of 6 patients (including 2 effective,
- the efficacy was higher than the efficacy, and the efficacy rate was 67%.
- a tablet consisting of the following composition was used to manufacture a therapeutic effect enhancer for the treatment of chronic viral hepatitis by the following method.
- Lactoferrin (Mirai) 20.0 (%) Bifidobacterium longong bacteria powder (Morinaga Dairy) 15.0 Lactulose (Morinaga Dairy) 20.0 Reduced maltose (Towa Kasei) 27 .6 Sweetener (Niken Kagaku) 15.2 Lubricant (RIKEN Vitamin) 1.8 Fragrance (Hasegawa Perfume) 0.4 Peri-lactoferrin, Bifidobacterium longum powder, lacturo-1 , A mixture of reduced maltose, a sweetener, a lubricant, and a flavor were tableted by a conventional method to give tablets.
- Example 2 Preparation of a tablet containing lactolactoferrin
- a tablet consisting of the following composition was prepared by the following method.
- Lactoferrin made by Mirai
- Lactose made by Morinaga Milk Products
- 18.5 Corn starch made by Nisshin Flour Milling
- Magnesium stearate made by Taihei Chemical Industry
- Carboxymethylcellulose calcium manufactured by Gotoku Pharmaceutical Co., Ltd.
- a syrup-based therapeutic effect enhancer of the following composition was prepared by a conventional method.
- Lactoferrin (manufactured by Mirai) 8.0 (%) Fructose dextrose liquid sugar (manufactured by Sanmatsu Kogyo) 12.4 Cuenoic acid (manufactured by Ueno Pharmaceutical) 0.2 Sodium citrate (manufactured by Maruzen Pharmaceutical) 0 .2 Carboxymethylcellulose calcium (manufactured by Gotoku Pharmaceutical Co., Ltd.) 0.2 Purified water (manufactured by Otsuka Pharmaceutical Co., Ltd.) 79.0
- a capsule therapeutic effect enhancer was manufactured. Lactose (Wako Pure Chemical Industries, Ltd.) 600 g, corn starch (Nisshin Flour Milling Co., Ltd.) 400 g s Microcrystalline cellulose (Wako Pure Chemical Industries, Ltd.) 400 g and ⁇ 'lactoferrin (Mirai Co., Ltd.) 600 g , Sieve through a 50 mesh sieve (manufactured by Yamato Scientific Co., Ltd.), place in a 0.5 mm thick polyethylene bag, mix by inversion, and The powder is packed in a capsule (manufactured by Elanco Japan, Inc., No. 1 gelatin capsule, Op. Yellow No. 6 Body, empty weight is 75 mg) using a filling machine (manufactured by Cesere Pedini, press type). The mixture was filled with 5 mg to obtain 7,000 capsules containing 82 mg of lactoferrin.
- the present invention has the following effects, and can be used in the fields of pharmaceuticals, health foods, and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002429793A CA2429793C (en) | 2000-11-29 | 2001-11-28 | Interferon therapeutic effect enhancer |
JP2002545722A JPWO2002043752A1 (ja) | 2000-11-29 | 2001-11-28 | インターフェロン治療効果増強剤 |
NZ525597A NZ525597A (en) | 2000-11-29 | 2001-11-28 | Interferon therapeutic effect-potentiating agents |
KR10-2003-7006510A KR20030060931A (ko) | 2000-11-29 | 2001-11-28 | 인터페론 치료효과 증강제 |
US10/432,551 US20040013642A1 (en) | 2000-11-29 | 2001-11-28 | Interferon therapeutic effect-potentiating agents |
AU2002222557A AU2002222557A1 (en) | 2000-11-29 | 2001-11-28 | Interferon therapeutic effect-potentiating agents |
EP01998362A EP1352657A4 (en) | 2000-11-29 | 2001-11-28 | INTERFERON-BASED EFFECT POTENTIALIZING THERAPEUTICS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000362813 | 2000-11-29 | ||
JP2000-362813 | 2000-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002043752A1 true WO2002043752A1 (fr) | 2002-06-06 |
Family
ID=18834024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/010383 WO2002043752A1 (fr) | 2000-11-29 | 2001-11-28 | Agents therapeutiques de potentialisation d'effet a base d'interferon |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040013642A1 (ja) |
EP (1) | EP1352657A4 (ja) |
JP (1) | JPWO2002043752A1 (ja) |
KR (1) | KR20030060931A (ja) |
CN (1) | CN1596123A (ja) |
AU (1) | AU2002222557A1 (ja) |
CA (1) | CA2429793C (ja) |
NZ (1) | NZ525597A (ja) |
WO (1) | WO2002043752A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004352669A (ja) * | 2003-05-29 | 2004-12-16 | Snow Brand Milk Prod Co Ltd | ラクトフェリン組成物 |
WO2007001006A1 (ja) | 2005-06-29 | 2007-01-04 | Nrl Pharma, Inc. | 重金属障害改善剤およびそれを含有する医薬組成物、食品、化粧料 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6657455B2 (en) * | 2000-01-18 | 2003-12-02 | Formfactor, Inc. | Predictive, adaptive power supply for an integrated circuit under test |
US20070191264A1 (en) * | 2005-05-05 | 2007-08-16 | Bristol-Myers Squibb Company, A Delaware Corporation | Methods for inhibiting the growth of bacteria |
EP1940905B1 (de) * | 2005-10-25 | 2010-08-11 | Evonik Degussa GmbH | Präparate umfassend hyperverzweigte polymere |
DE102005051366A1 (de) * | 2005-10-25 | 2007-04-26 | Degussa Gmbh | Drug Delivery Systeme |
EP1982698A1 (de) * | 2007-04-18 | 2008-10-22 | Evonik Degussa GmbH | Präparate zur gesteuerten Freisetzung von bioaktiven Naturstoffen |
WO2009031918A1 (ru) * | 2007-09-05 | 2009-03-12 | Shatunovsky Nikolai Evgenievic | Композиции аполактоферрина и способы их применения в лечении вирусного гепатита с |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6351337A (ja) * | 1986-08-22 | 1988-03-04 | Snow Brand Milk Prod Co Ltd | 抗腫瘍剤 |
JPH07188052A (ja) * | 1993-12-27 | 1995-07-25 | Sanwa Kagaku Kenkyusho Co Ltd | インターフェロン用作用効果増強剤及び該増強剤とインターフェロンとを含有する抗ウイルス活性増強組成物 |
WO1999065329A2 (en) * | 1998-06-16 | 1999-12-23 | Regen Biotech Limited | Dietary supplement containing colostrinin |
WO2000006192A1 (fr) * | 1998-07-30 | 2000-02-10 | Morinaga Milk Industry Co., Ltd. | Agents ameliorant la fonction hepatique |
JP2000325046A (ja) * | 1999-05-19 | 2000-11-28 | Meiji Milk Prod Co Ltd | 肝炎を予防および治療する食品もしくは医薬品 |
WO2001047545A1 (fr) * | 1999-12-28 | 2001-07-05 | Sumitomo Pharmaceuticals Company, Limited | Produits therapeutiques et prophylactiques pour l'hepatique chronique |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3312946B2 (ja) * | 1993-03-04 | 2002-08-12 | 雪印乳業株式会社 | ウイルス感染・増殖抑制剤 |
US5814485A (en) * | 1995-06-06 | 1998-09-29 | Chiron Corporation | Production of interferon-β (IFN-β) in E. coli |
-
2001
- 2001-11-28 JP JP2002545722A patent/JPWO2002043752A1/ja active Pending
- 2001-11-28 CN CNA018196047A patent/CN1596123A/zh active Pending
- 2001-11-28 CA CA002429793A patent/CA2429793C/en not_active Expired - Fee Related
- 2001-11-28 NZ NZ525597A patent/NZ525597A/en not_active IP Right Cessation
- 2001-11-28 WO PCT/JP2001/010383 patent/WO2002043752A1/ja not_active Application Discontinuation
- 2001-11-28 AU AU2002222557A patent/AU2002222557A1/en not_active Abandoned
- 2001-11-28 KR KR10-2003-7006510A patent/KR20030060931A/ko not_active Application Discontinuation
- 2001-11-28 US US10/432,551 patent/US20040013642A1/en not_active Abandoned
- 2001-11-28 EP EP01998362A patent/EP1352657A4/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6351337A (ja) * | 1986-08-22 | 1988-03-04 | Snow Brand Milk Prod Co Ltd | 抗腫瘍剤 |
JPH07188052A (ja) * | 1993-12-27 | 1995-07-25 | Sanwa Kagaku Kenkyusho Co Ltd | インターフェロン用作用効果増強剤及び該増強剤とインターフェロンとを含有する抗ウイルス活性増強組成物 |
WO1999065329A2 (en) * | 1998-06-16 | 1999-12-23 | Regen Biotech Limited | Dietary supplement containing colostrinin |
WO2000006192A1 (fr) * | 1998-07-30 | 2000-02-10 | Morinaga Milk Industry Co., Ltd. | Agents ameliorant la fonction hepatique |
JP2000325046A (ja) * | 1999-05-19 | 2000-11-28 | Meiji Milk Prod Co Ltd | 肝炎を予防および治療する食品もしくは医薬品 |
WO2001047545A1 (fr) * | 1999-12-28 | 2001-07-05 | Sumitomo Pharmaceuticals Company, Limited | Produits therapeutiques et prophylactiques pour l'hepatique chronique |
Non-Patent Citations (2)
Title |
---|
ISHII KOJI ET AL.: "Effect of lactoferrin for patients with chronic hepatitis C", HEPATOLOGY, vol. 32, no. 4, October 2000 (2000-10-01), pages 444A, XP002909013 * |
See also references of EP1352657A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004352669A (ja) * | 2003-05-29 | 2004-12-16 | Snow Brand Milk Prod Co Ltd | ラクトフェリン組成物 |
JP4592260B2 (ja) * | 2003-05-29 | 2010-12-01 | 雪印乳業株式会社 | ラクトフェリン組成物 |
WO2007001006A1 (ja) | 2005-06-29 | 2007-01-04 | Nrl Pharma, Inc. | 重金属障害改善剤およびそれを含有する医薬組成物、食品、化粧料 |
Also Published As
Publication number | Publication date |
---|---|
CA2429793A1 (en) | 2002-06-06 |
NZ525597A (en) | 2004-11-26 |
KR20030060931A (ko) | 2003-07-16 |
CN1596123A (zh) | 2005-03-16 |
EP1352657A1 (en) | 2003-10-15 |
US20040013642A1 (en) | 2004-01-22 |
AU2002222557A1 (en) | 2002-06-11 |
CA2429793C (en) | 2009-04-28 |
EP1352657A4 (en) | 2004-06-16 |
JPWO2002043752A1 (ja) | 2004-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0559425B1 (en) | Use of proteins belonging to the transferrin/lactoferrin family for potentiating the immune system | |
CN1329030C (zh) | 肝癌发生·发展抑制剂 | |
JP3853673B2 (ja) | C型慢性肝炎治療剤 | |
TWI269656B (en) | Therapeutical composition for hepatitis C | |
WO2012009503A1 (en) | Palatable pharmaceutical composition comprising vx-950 | |
JP5555401B2 (ja) | C型肝炎ウイルス陽性ヒト肝硬変患者用肝癌発生・進展抑制剤 | |
WO2002043752A1 (fr) | Agents therapeutiques de potentialisation d'effet a base d'interferon | |
US6017946A (en) | Serotonin containing formulation for oral administration and method of use | |
JPH08503964A (ja) | 食餌療法の低コレステロール血組成物 | |
JP4087249B2 (ja) | B型慢性肝炎治療剤 | |
WO2000006192A1 (fr) | Agents ameliorant la fonction hepatique | |
JP2001247474A (ja) | 肝疾患予防及び/又は治療剤 | |
JP2002322086A (ja) | ヘリコバクター・ピロリ感染予防治療剤並びに感染予防治療用飲食品 | |
JP5484704B2 (ja) | 高齢者の発熱症状抑制剤 | |
JP7291380B2 (ja) | 鼻水又は鼻づまりの口腔粘膜投与用即効性改善剤 | |
WO2023016389A1 (zh) | 包含β-烟酰胺单核苷酸和绿原酸的组合物及其应用 | |
JP4792561B2 (ja) | ヒト免疫不全ウイルス感染・増殖抑制剤 | |
JPH11171763A (ja) | 肝疾患治療剤 | |
WO2022093922A1 (en) | Use of a cinnamein composition for the treatment of glycine encephalopathy and urea cycle disorders | |
JPS6360926A (ja) | 感冒薬 | |
CN101180053A (zh) | 铁在发病机制中发挥作用的肝病的治疗 | |
JP2004099610A (ja) | 肝性脳症改善剤 | |
Frye et al. | and Adverse Effects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN ID IN JP KR NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 533/KOLNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 525597 Country of ref document: NZ Ref document number: 2002222557 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037006510 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2429793 Country of ref document: CA Ref document number: 10432551 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001998362 Country of ref document: EP Ref document number: 018196047 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002545722 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037006510 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001998362 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 525597 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 525597 Country of ref document: NZ |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020037006510 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001998362 Country of ref document: EP |